Jump to content

Stents for LBO

From Surgopaedia

Selecting a stentable lesion

[edit | edit source]
  • Best between splenic flexure and rectosigmoid
  • Rectum beyond rectosigmoid junction generally causes unbearable tenesmus, and carries a high risk of stent migration
  • Areas of acute angulation (flexures) are hard in general
  • Proximal colon is hard, but theoretically feasible by specialists

Indications (generally only malignant indications at this stage)

[edit | edit source]
  • Palliation for patients not fit for resection, or with widespread metastases
  • Pre-operative decompression
    • Clinical stabilisation
    • Allow bowel prep
    • Pre-op colonoscopy to exclude synchronous lesions
    • Allows one-stage resection and anastomosis
    • Operate 5-10 days later

Equipment

[edit | edit source]
  • Covered vs uncovered
    • Covered are less likely to get tumour ingrowth (3.8% vs 14.5%)
    • Uncovered are less likely to migrate (1.8% vs 21.1%)
    • Uncovered are generally preferred
  • Generally deployed through the scope

Preparation

[edit | edit source]
  • In partial obstruction, prep gently with PEG
  • In complete obstruction, consider giving an enema
  • Prophylactic Abx
  • If in doubt about ability to traverse and stent, give a contrast enema - if contrast won't pass, neither will the guidewire

Technique

[edit | edit source]
  • Try to pass the lesion
  • Don't dilate the lesion
  • Pass a guidewire
  • Confirm placement with fluoroscopy
  • Pass stent over the top and expand in 1-2cm increments with fluoroscopy guidance

Post-procedure

[edit | edit source]
  • Low-residue diet
    • Avoid vegetables, fruits and whole grains
  • Stool softeners

Efficacy

[edit | edit source]
  • Technical success - 97%
  • Able to decompress colon through stent within 96 hours - 97%
  • For palliation, rate of reintervention is 20%

Complications

[edit | edit source]
  • Perforation (<5%)
    • Immediate or delayed (erosion)
    • High-risk with bevacizumab or radiation
  • Migration 11%
    • High risk
      • Benign lesions (doesn't embed)
      • Stent too small
      • Tumour shrinks after therapy
  • Rectal bleeding - significant bleeding is rare
  • Recurrent obstruction
    • Tumour can grow in at ends of stent or through the stent - can be treated by argon photocoagulation or laser or another stent